Skip to main content

Advertisement

Table 1 Characteristics of naive subjects with and without presumed advanced fibrosis

From: Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

Characteristics Subjects with presumed fibrosis1 reinvestigated Subjects with presumed fibrosis1 not reinvestigated Subjects without presumed fibrosis
Number of subjects 105 104 7254
Age at serum, years (mean;95%CI) 66.5 (64.7-68.2) 63.6 (62.0-65.2) 56.7 (56.5-56.9)
Male (%; 95%CI) 94 (0.90;0.82-0.95) 95 (0.91;0.84-0.96) 3924 (0.54;0.53-0.55)
Tobacco consumption 63/105 (0.60;0.50-0.69) 54/104 (0.52;0.42-0.62) 3245/7247 (0.45;0.44-0.46)
No physical exercise 65/105 (0.62;0.52-0.71) 60/104 (0.58;0.48-0.67) 4685/7247 (0.65;0.64-0.66)
Retired 70 (0.67;0.57-0.76) 58 (0.56;0.46-0.66) 2224 (0.31;0.30-0.32)
Fatty liver risk factor (Alcohol or metabolic) 98 (0.93;0.87-0.97) 86 (0.83;0.74-0.89) 4698 (0.65;0.64-0.66)
Mean daily self-reported alcohol consumption 11.6 (8.2-15.0) 15.3 (11.4-19.3) 9.9 (9.6-10.3)
Self-reported alcohol consumption at risk2 24/105 (0.23;0.15-0.32) 28/104 (0.27;0.19-0.37) 1634/7247 (0.23;0.22-0.24)
CDT assessed 72/105 (0.69;0.59-0.77) 2/104 (0.02;0.00-0.07) 1023/7254 (0.14;0.13-0.15)
Carbohydrate Deficient Transferin 1.92 (1.76-2.07) 1.49 (1.24-1.74) 1.51 (1.48-1.54)
Elevated Carbohydrate Deficient Transferin (>1.6%)3 45/72 (0.63;0.50-0.74) NP 303/1023 (0.30;0.27-0.33)
Alcohol at risk (either reported consumption or CDT)3 54/72 (0.75;0.63-0.85) NP 426/1023 (42%)
BMI >= 27.0 57 (0.54;0.44-0.64) 49 (0.47;0.37-0.57) 2319/7245 (0.32;0.31-0.33)
Metabolic factor of ATP-III classification (at least one) 83 (0.79;0.70-0.86) 80 (0.77;0.68-0.85) 3827 (0.53;0.52-0.54)
Glucose >= 6.1 mmol/L or diabetes treatment 34/103 (0.33;0.24-0.43) 42/104 (0.40;0.31-0.51) 1069/7253 (0.15;0.14-0.16)
Central obesity waist >102 male >88 female 30/105 (0.29;0.20-0.38) 28/104 (0.27;0.19-0.37) 1162/7245 (0.16;0.15-0.17)
Triglycerides >= 1.7 mmol/L or fibrate treatment 43/101 (0.41;0.32-0.51) 37/104 (0.36;0.26-0.46) 1707/7199 (0.24;0.23-0.25)
Hypertension or treatment 44/105 (0.42;0.32-0.52) 41/104 (0.39;0.30-0.50) 1885/7240 (0.26;0.25-0.27)
HDL-cholesterol <1.03 mmol/L male <1.29 mmol/L female missing 2564 16/72 (0.22;0.13-0.34) 12/68 (0.18; 0.10-0.29) 328/4764 (0.07;0.06-0.08)
Steatosis predicted by SteatoTest    
No 23/101 (0.23;0.15-0.32) 31/104 (0.30;0.21-0.40) 4174/7190 (0.58;0.57-0.59)
Minimal (1-5%) 37/101 (0.37;0.27-0.47) 33/104 (0.32;0.23-0.42) 1617/7190 (0.23;0.22-0.24)
Moderate (6-33) 19/101 (0.19;0.12-0.28) 15/104 (0.14;0.08-0.23) 706/7190 (0.10;0.09-0.11)
Marked-Severe (34-100%) 22/101 (0.22;0.14-0.31) 25/104 (0.24;0.16-0.33) 693/7190 (0.10;0.09-0.10)
Steatohepatitis predicted by NASHTest 7/101 (0.07;0.03-0.13) 11/104 (0.11;0.05-0.18) 62/7190 (0.009;0.007-0.011)
Risk HCV (Transfusion, tattoo, piercing, heroin, cocaine) 1 (0.010;0.000-0.052) 1 (0.010;0.000-0.052) 163 (0.023;0.019-0.026)
HCV antibody assessed 105/105 (1.00;0.97-1.00) 52/104 (0.50;0.40-0.60) 3473/7254 (0.48;0.47;0.49)
HCV antibody positive 5/105 (0.05;0.02-0.11) 1/52 (0.02;0.00-0.10) 26/3473 (0.008;0.005-0.011)
HIV antibody positive 1/63 (0.02;0.00-0.09) 0/6 (0.00;0.00-0.46) 1/944 (0.001;0.000-0.006)
HBsAg assessed 105/105 (1.00;0.97-1.00) 8/104 (0.08;0.03-015) 604/7254 (0.08;0.077-0.090)
HBsAg antigen positive 2/105 (0.02;0.00-0.07) 0/104 (0.00;0.00-0.04) 5/604 (0.008; 0.003-0.019)
Liver stiffness measurement assessed 93/105 (0.86;0.81-0.94) 0/104 (0.00;0.00-0.04) 865/7254 (0.12;0.11-0.13)
LSM kPa 10.1 (8.3-12.0) NP 5.0 (4.8-5.1)
Markers (normal range)    
AST IU/L (17-27 female; 20-32 male) 34 (31-37) 40 (34-46) 24 (24-24)
ALT IU/L (11-26 female; 16-35 male) 43 (37-50) 46 (38-54) 27 (26-27)
Total bilirubin mol/L (1-21) 16 (14-17) 16 (14-17) 12 (12-12)
GGT U/L (7-32 female; 11-49 male) 72 (56-87) 111 (75-146) 27 (26-27)
Alpha 2 macroglobulin g/L (female 1·6-4·0; male 1·4-3·3) 2.4 (2.3-2.5) 2.4 (2.3-2.5) 1.5 (1.5-1.5)
Apo A1 g/L (1·2-1·7) 1.5 (1.4-1.5) 1.5 (1.4-1.5) 1.7 (1.7-1.7)
Haptoglobin g/L (0·35-2·00) 0.9 (0.8-1.0) 0.8 (0.7-0.9) 1.2 (1.1-1.2)
Fasting Glucose (mmol/L) 6.1 (5.8-6.4) 6.4 (6.0-6.8) 5.5 (5.5-5.5)
Cholesterol (mmol/L) 5.3 (5.1-5.5) 5.4 (5.1-5.6) 5.8 (5.7-5.8)
Triglycerides (mmol/L) 1.7 (1.3-2.0) 1.8 (1.4-2.2) 1.3 (1.3-1.3)
HDL-cholesterol (data in 72/68/4764 subjects) 0.49 (0.46-0.51) 0.51 (0.47-0.54) 0.63 (0.62-0.63)
  1. 1 FibroTest greater than 0.48
  2. 2 More than one drink per day for females and more than two drinks per day for males
  3. Data are mean (SD) or proportion.
  4. 3 Carbohydrate Deficient Transferin was consecutively assessed in 1038 subjects at baseline and in 59 subjects during reinvestigations.